C5 and paroxysmal nocturnal hemoglobinuria: Here, we provide additional information on the interaction between zilucoplan and complement C5 and the ability of zilucoplan to prevent the activation of C5 in both wild-type and two clinically relevant variants (R885C/H) that have been shown to be resistant to eculizumab treatment in PNH patients carrying such polymorphisms (16).